ENA Respiratory raises $3.0M Grant (Australia, Sep 2026)
Reach the investors backing rounds like this
Backed by Biointelect Venturer program · verified emails and LinkedIn on Datapile
Viral infections biotech ENA Respiratory inhales $3 million from government fund - Startup Daily
ENA Respiratory is a clinical-stage biotech company developing an antiviral nasal spray, INNA-051, to strengthen the body's first line of defense against respiratory viruses like influenza, RSV, and COVID-19. This $3 million grant will fund a trial in adults with asthma to assess the treatment's safety and efficacy, aiming to reduce complications from respiratory infections in high-risk groups.
Viral infections biotech ENA Respiratory inhales $3 million from government fund Startup Daily
| Sep 25, 2026 | Medcast | $5.4M | — | Australia |
| Sep 25, 2026 | RentBetter | $5.0M | — | Australia |
| Sep 23, 2026 | Heidi | $340.0M | — | Australia |
| Sep 23, 2026 | Kinoxis Therapeutics | $6.8M | Grant | Australia |
14,106 investors back startups in Australia
You just read who funded ENA Respiratory. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.